What are the main limitations or barriers to integrating gene expression profiling into routine melanoma management in your practice?

There have been about 250,000 tests done in the country. Around 40% of melanomas each year are tested, and somewhere around 10,000 to 11,000 doctors use it, so access has not been much of a barrier.

As far as cost goes, everything has a cost, though patients do not pay for it. If the insurance compa...

We have no significant barriers to implementing GEP into the management of melanoma in our practice. We do what is best for patients. Any administrative hiccups are easily overcome with a phone call, a fax, or other minimal intervention. When we are dealing with life and death decisions, no effort i...

In an ideal world, I would have these results available to me at the first consultation or visit with the patient. It is imperative for the person performing the biopsy to order gene expression profiling (GEP) DecisionDx-Melanoma so that all possible information is available to me and the patient as...